Avid Bioservices, Inc. (NASDAQ:CDMO) Q1 2024 Earnings Conference Call September 7, 2023 4:30 PM ET Dan Hart - Chief Financial Officer Matt Hewitt - Craig-Hallum I would now like to hand the conference over to Tim Brons of Avid's Investor Relations Group. Please go ahead. With that, I will turn the call over to Nick Green, Avid's President and CEO. We continue to successfully onboard new business won during the second half of fiscal '23 and our revenues during the period remained strong. In operations, the c ...

Item 6. Exhibits 26 Form 10-Q TABLE OF CONTENTS Item 1. Condensed Consolidated Financial Statements 3 CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) (Unaudited) (In thousands, except per share information) AVID BIOSERVICES, INC. CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (Unaudited) (In thousands) AVID BIOSERVICES, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (In thousands) Note 1 – Description of Company and Basis of Presentation The ac ...

Company Participants Matt Kwietniak - Chief Commercial Officer Paul Knight - KeyBanc Capital Operator Tim Brons Before we begin, I'd like to caution that comments made during this conference call today, June 21st, 2023 will contain certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, concerning the current belief of the company, which involves a number of assumptions, risks, and uncertainties. Actual results could differ from these statements and the ...

If our existing cash on hand and our anticipated cash flows from operations are not sufficient to support our operations or capital requirements, including our cell and gene therapy facility expansion, then we may, in the future, draw on our existing revolving credit facility, which is subject to covenant compliance and availability (as described in Note 7 of the notes to consolidated financial statements) and/or obtain additional equity or debt financing to fund our future operations and/or such expansion. ...

Nick Green - President and Chief Executive Officer Company Participants Dan Hart - Chief Financial Officer Conference Call Participants Matt Hewitt - Craig-Hallum Paul Knight - KeyBanc Good day, ladies and gentlemen and welcome to the Avid Bioservices Third Quarter Fiscal 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference call maybe recorded. I would now like to hand the conference over to Tim Brons of AvidÂ's Investor Relations Group. Please go ahead. Thank you. ...

Debt Issuance Costs Comprehensive Income Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Delaware (State or other jurisdiction of incorporation or organization) 95-3698422 (I.R.S. Employer Identification No.) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such r ...

Avid Bioservices, Inc. (NASDAQ:CDMO) Q2 2023 Results Conference Call December 6, 2022 4:30 PM ET Company Participants Tim Brons - IR Nick Green - President and CEO Dan Hart - CFO Matt Kwietniak - Chief Commercial Officer Conference Call Participants Sean Dodge - RBC Capital Markets Matt Hewitt - Craig-Hallum Capital Group Jacob Johnson - Stephens Paul Knight - KeyBanc Operator Good day, ladies and gentlemen. And welcome to the Avid Bioservices Second Quarter Fiscal 2023 Financial Results Conference Call. At ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended October 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number: 001-32839 AVID BIOSERVICES, INC. (Exact name of Registrant as specified in its charter) Delaware (State or oth ...

Avid Bioservices, Inc. (NASDAQ:CDMO) Q1 2023 Earnings Conference Call September 6, 2022 4:30 PM ET Company Participants Tim Brons - Investor Relations Nick Green - President and Chief Executive Officer Dan Hart - Chief Financial Officer Matt Kwietniak - Chief Commercial Officer Conference Call Participants Thomas Kelliher - RBC Capital Markets Jacob Johnson - Stephens Matt Hewitt - Craig-Hallum Paul Knight - KeyBanc Operator Good day, ladies and gentlemen. Welcome to the Avid Bioservices First Quarter Fisca ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended July 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____ Commission file number: 001-32839 AVID BIOSERVICES, INC. (Exact name of Registrant as specified in its charter) Delaware (State or other ...